Final Program
h6okmgq
h6okmgq
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
264 TUESDAY • MAY 17<br />
P428<br />
P429<br />
P430<br />
P431<br />
P432<br />
P433<br />
P434<br />
P435<br />
P436<br />
P437<br />
P438<br />
P439<br />
The Preliminary Evaluation of the Effectiveness and Safety of<br />
/L. Shen, Q.H.<br />
Li, D. Weng, Shanghai, China, p.A5010<br />
Phase 1 LPS Challenge Study of the Safety, Tolerability,<br />
Pharmacokinetics (PK) and Pharmacodynamics of Multi-Day<br />
Inhaled (IH) Dosing of the MAPKAP Kinase II (MK2) Inhibitor,<br />
MMI-0100, in Subjects Who Smoke/W. Bradford, C. Peterson,<br />
C.M. Brophy, P.W. Noble, A. Panitch, C. Lander, A.D. Luber, G.<br />
Nicolson, B. Leaker, Morristown, NJ, p.A5011<br />
A Retrospective Analysis to Assess the Clinical Significance of<br />
an Isolated Reduction in Residual Volume/A. Kumar, J.D. Lopez,<br />
T. Salim, A. Sahni, A. Tulaimat, S.S. Fakhran, Chicago, IL, p.A5012<br />
Relationship Between Systemic and Localized Inflammatory<br />
Protein Expression in Combined Pulmonary Fibrosis and<br />
Emphysema (CPFE), Interstitial Pulmonary Fibrosis, and<br />
Emphysema/W. Cornwell, C. Kim, A.C. Lastra, C. Dass, S. Bolla,<br />
H. Wang, N. Marchetti, T.J. Rogers, G.J. Criner, Philadelphia, PA,<br />
p.A5013<br />
Correlation of Clinical Characteristics by the Grade of<br />
Pulmonary Emphysema in Combined Pulmonary Fibrosis and<br />
Emphysema/K. Sugino, Y. Nakamura, K. Gocho, G. Sano, K.<br />
Isobe, S. Sakamoto, Y. Takai, S. Homma, Tokyo, Japan, p.A5014<br />
Combined Pulmonary Fibrosis and Emphysema: A Novel<br />
Evaluation of Lung Tissue Proteins/A.C. Lastra, C. Kim, W.D.<br />
Cornwell, C. Dass, S. Bolla, T.J. Rogers, H. Wang, N. Marchetti,<br />
G.J. Criner, Philadelphia, PA, p.A5015<br />
Different Genetic Characteristic Profiles of Combined<br />
Pulmonary Fibrosis and Emphysema/H. Qiu, D. Weng,<br />
Shanghai, China, p.A5016<br />
Computed Tomograpy Findings of Pleuroparenchymal<br />
Fibroelastosis Patients After Single Lung Transplantation/Y.<br />
Waseda, C. Halder, H. Prosch, C. Herold, K. Kasahara, C.<br />
Lambers, Kanazawa, Japan, p.A5017<br />
Efficacy of Concurrent Treatments in Rapidly Progressive<br />
Idiopathic Pulmonary Fibrosis/K. Oda, K. Yatera, H. Ishimoto, H.<br />
Mukae, Japan, p.A5018<br />
Dietary Patterns and Subclinical Interstitial Lung Disease: The<br />
MESA Lung Fibrosis Study/J. Sell, S.M. Kawut, A. Podolanczuk,<br />
G. Raghu, W. Karmally, E.D. Michos, R.G. Barr, D.R. Jacobs, Jr.,<br />
D.J. Lederer, New York, NY, p.A5019<br />
Cardiovascular Medication Use and Subclinical Interstitial<br />
Lung Disease: The MESA Lung Fibrosis Study/M.D. Restivo, J.<br />
Sell, A. Podolanczuk, S.M. Kawut, G. Raghu, E.D. Michos, R.G.<br />
Barr, D.J. Lederer, New York, NY, p.A5020<br />
Evaluation of the Healthcare Burden of Idiopathic Pulmonary<br />
Fibrosis (IPF) in Fife, Scotland/D.J. Dhasmana, F. Harrison, T.<br />
Hartley, D. Szapiro, United Kingdom, p.A5021<br />
C40<br />
THEMATIC POSTER SESSION<br />
SARCOIDOSIS: UNDERSTANDING THIS<br />
MULTI-SYSTEM DISORDER<br />
9:00 a.m. - 4:15 p.m. MOSCONE CENTER<br />
Viewing: Posters will be on display for entire session.<br />
Area C, Hall D (North Building, Lower Level)<br />
Discussion: 11:00-11:45: authors will be present for individual discussion<br />
11:45-12:45: authors will be present for discussion with assigned facilitators<br />
Facilitator:<br />
P237<br />
P238<br />
P239<br />
P240<br />
P241<br />
P242<br />
P243<br />
Facilitator:<br />
P244<br />
P245<br />
P246<br />
G.E. Westney, MD, Atlanta, GA<br />
Lung Function Tests in Patients with Sarcoidosis Related<br />
Pulmonary Hypertension/V. Kouranos, A.U. Wells, J.B. Barney,<br />
D.A. Culver, M.B. Scholand, E.M. Carmona, E. Alhamad, O.A.<br />
Shlobin, F. Cordova, B. Van Den Blink, R.P. Baughman, United<br />
Kingdom, p.A5022<br />
Serum Chitotriosidase as Indicator of Disease Activity in<br />
Sarcoidosis Patients/S. Filipovic-Stepic, V. Vucinic-Mihailovic, Z.<br />
Sumarac, J. Videnovic-Ivanov, M. Stjepanovic, M. Omcikus,<br />
Belgrade, Serbia, p.A5023<br />
Implementation of Electronic Medical Record (EMR) Checklist<br />
to Improve Compliance with Chronic Steroid Management<br />
Recommendations of Pulmonary Patients/O. Nadeem, S.K.<br />
Avasarala, F. Cheema, L. Yessayan, K. Thavarajah, Detroit, MI,<br />
p.A5024<br />
Resolution of Cardiac Magnetic Resonance T2 Signal<br />
Following Immune Suppression for Cardiac Sarcoidosis: A<br />
Case Series/E. Ruden, E. Jackson, S. Raman, E.D. Crouser,<br />
Columbus, OH, p.A5025<br />
Impact of Metabolic Disorders on Pulmonary Sarcoidosis/N.<br />
Durairajan, B. Thapa, H. Bokaie, L. Samavati, Detroit, MI, p.A5026<br />
Assessment of Myocardial Inflammation by FDG-PET as a<br />
Guide to Immunosuppressive Therapy of Cardiac<br />
Sarcoidosis/S.R. Russell, A.E. Pender, A.B. Chicos, P.H. Sporn,<br />
Chicago, IL, p.A5027<br />
Association of Calcified Lymph Nodes on Thoracic Computed<br />
Tomography and Severity of Pulmonary Disease in<br />
Sarcoidosis/Y. Kawar, V. Ortiz, J. Jennings, L. Yessayan, K.<br />
Thavarajah, Detroit, MI, p.A5028<br />
R.P. Baughman, MD, Cincinnati, OH<br />
Using Impulse Oscillation to Detect Airflow Limitation in<br />
Pulmonary Sarcoidosis/P.W. Kicker, K. Sheikh, S.C. Parrish, A.<br />
Holley, Bethesda, MD, p.A5029<br />
Castleman Disease Associated Diffuse Parenchymal Lung<br />
Disease: A Retrospective Analysis of 21 Cases in a Tertiary<br />
Chinese Hospital/H. Huang, X. Song, S. Li, K. Xu, Y. Bi, R. Feng,<br />
Z. Xu, Beijing, China, p.A5030<br />
Is the Neutrophil-to-Lympocyte Ratio Different in Sarcoidosis<br />
and Interstitial Lung Diseases?/Z. Karakurt, U. Aka Akturk, N.<br />
Durmus Kocak, M. Yalcinsoy, S. Gungor, E. Aksoy, B. Gundogus,<br />
L. Sertcelik, M. Coban Agca, D. Duman, S. Oztas, D. Yavuz, H.<br />
Ozgen, T. Sevim, E. Akkaya, Istanbul, Turkey, p.A5031<br />
ATS 2016 • San Francisco
Change language